Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olga Chernova

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Folia Medica|April 28, 2020
Peak Responses during Exercise Treadmill Testing using Individualized Ramp Protocol and Modified Bruce Protocol in Elderly PatientsSergey Kozlov, Martin Caprnda, Olga Chernova, et al.
Journal of Neurosurgery|April 20, 2006
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision makingAndrew A Kanner, Susan M Staugaitis, Elias A Castilla, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Folia Medica|April 28, 2020
Peak Responses during Exercise Treadmill Testing using Individualized Ramp Protocol and Modified Bruce Protocol in Elderly PatientsSergey Kozlov, Martin Caprnda, Olga Chernova, et al.
Journal of Neurosurgery|April 20, 2006
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision makingAndrew A Kanner, Susan M Staugaitis, Elias A Castilla, et al.
Leukemia|December 19, 2019
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaKlaartje Somers, Kathryn Evans, Leanna Cheung, et al.
Molecular Cancer Therapeutics|October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Pageof 2